Medicenna Therapeutics Corp. (MDNA) Social Stream
Medicenna Therapeutics Corp (MDNA) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering MDNA.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
MDNA's average price target has moved down $2.51 over the prior 44 weeks.
Over the past 48 weeks, MDNA's average upside potential has been 312.97%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
MDNA Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 48 weeks, MDNA's average broker recommendation rating improved by 1.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, Medicenna Therapeutics Corp's upside potential (average analyst target price relative to current price) is higher than 390.78% of them.
- To contextualize these metrics, consider that out of all US stocks, Medicenna Therapeutics Corp's average analyst price target is greater than 34.31% of them.
- MDNA has a higher number of analysts covering the stock than 338.08% of stocks in the micro market cap category.
- In the context of stocks in the micro market cap category, Medicenna Therapeutics Corp's variance in analysts' estimates is lower than -188.82% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Medicenna Therapeutics Corp are MBRX, LTRN, and LPTX.
Is MDNA a Buy, Hold or Sell? See the POWR Ratings now!